future of protein production with plates with healthy food and protein

Are you submitting too early? The hidden risks of premature novel food and GRAS submission

April 28, 2026

For many companies developing innovative food ingredients, regulatory submission is seen as a critical milestone to be achieved as quickly as possible, both to de-risk the business and to satisfy investor expectations. For investor-backed companies, filing a novel food dossier or a Generally Recognized as Safe (GRAS) notification can act as a trigger to unlock funding and demonstrate momentum.

However, filing too early, before the dataset, narrative and regulatory strategy are fully mature, can introduce risks that are far more difficult to manage than a delayed submission.

In the USA, a premature GRAS notification can result in the FDA identifying significant gaps and, in some cases, requesting the notifier to withdraw. Although this may seem like a manageable outcome, withdrawals are published in the GRAS notice inventory and can raise questions around both the robustness of the notification and the underlying safety conclusion. In some cases, if the notification is filed, the FDA may instead conclude that the notice does not provide a sufficient basis for a GRAS conclusion or cease to evaluate the notice at the notifier’s request. This can significantly impact the perception of the ingredient among future customers, partners and consumers.

The cost of submitting too early is often far greater than the cost of waiting a little longer to get it right

In the EU, the equivalent risk manifests differently. An incomplete dossier will struggle during validation, leading to delays before the European Food Safety Authority (EFSA) even begins its scientific risk assessment. Once under review, data gaps can trigger clock-stops and additional data requests, significantly extending timelines.

Regulators operate under increasing resource pressures, and poorly prepared submissions do not go unnoticed. Submitting incomplete dossiers that do not align with the guidance and require substantial follow-up can erode credibility and goodwill with authorities. Premature filings risk being perceived as an inefficient use of regulatory resources, effectively clogging review pipelines. Over time, this can influence not only the efficiency of future reviews but also the tone of future interactions.

There is also a risk in locking in key aspects of the ingredient too early. A dossier or notification defines the manufacturing process, specifications and intended uses. Submitting before these are fully optimized can result in authorization for a process that is not yet commercially viable or scalable. As companies optimize the production process, either to improve yield, reduce costs or scale manufacturing, these changes may fall outside the scope of the original authorization. In the EU, this can require a modification of use or a new application; in the USA, it may necessitate an amendment or a new GRAS notification. Frequent changes not only introduce costs and delays but can also reinforce the perception of an evolving or unstable production process.

These risks are not trivial, but neither is the pressure companies face. Development timelines are long, approval timelines are long, production at scale is challenging, and generating sufficient material to support toxicological and analytical testing is resource-intensive. Many companies simply do not have the luxury of waiting and must balance regulatory readiness with commercial urgency.

However, this is precisely why submission should be treated as a strategic decision, not simply a milestone to satisfy external pressure. Taking additional time to strengthen the dataset, refine the narrative and anticipate regulatory questions can ultimately accelerate the path to a successful outcome. The cost of submitting too early is often far greater than the cost of waiting a little longer to get it right. Paradoxically, trying to move faster can ultimately slow you down.

Dr Hannah Lester is the CEO of Atova Regulatory Consulting and also Head of Regulatory Strategy at Gourmey. This article is republished from the Q1 2026 edition of Protein Production Technology International, the industry's leading resource for alternative proteins. To subscribe to all future editions, please click here

If you have any questions or would like to get in touch with us, please email info@futureofproteinproduction.com

About the Speaker

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.